NLGN1 and neoplasm: The remaining three mutations showed a reduced amount; however, they were still detectable to a significant extent: TRPC7-rs566980923 (ID = 1148), 12.5% in tumor and 4.9% in PF; AMPH-COSM1673120 (ID = 2324), 15.1% (tumor) and 4.01% (PF); NLGN1-COSM479730 (ID = 2438), 21.95% and 1.59%, respectively (Table 1).